GlassScriptPhysician profile
Michael A Mcdonald
NPI 1265413793
$4,126.82
in general payments reported to CMS, 2019-2025
28 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $852 · 2022: $1,159 · 2023: $1,110 · 2024: $467 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Education: $17.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.68 |
| Education | $17.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $889.37 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $382.52 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $249.62 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Ardelyx, INC. | $221.12 | 2022-2025 | Ibsrela |
| Celgene Corporation | $187.78 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $120.54 | 2021-2023 | |
| Qol Medical, LLC | $101.94 | 2021-2024 | Sucraid |
| Pentax of America, INC. | $82.49 | 2022 | |
| Braintree Laboratories, INC. | $79.25 | 2022-2024 | Sutab |
| Ironwood Pharmaceuticals, INC | $71.83 | 2021-2023 | Linzess |
| Redhill Biopharma INC. | $69.44 | 2021-2022 | |
| Gilead Sciences, INC. | $65.44 | 2023-2024 | |
| Genzyme Corporation | $58.30 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $51.22 | 2021-2023 | Ocaliva |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $49.78 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $48.90 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $45.46 | 2022-2024 | Dupixent |
| Novo Nordisk INC | $42.90 | 2025 | Wegovy |
| Lilly USA, LLC | $40.62 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $34.83 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $34.27 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $32.94 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $27.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $25.15 | 2022 | |
| Organon LLC | $24.69 | 2023 | Renflexis |
| Amgen INC. | $23.44 | 2022 | |
| Celltrion USA INC. | $17.17 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.